A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK Plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma

PURPOSE: Based on preclinical evidence of synergistic activity between MEK and EGFR inhibitors in pancreatic ductal adenocarcinoma (PDAC), we evaluated the safety and efficacy of selumetinib, a MEK1/2 inhibitor, plus erlotinib in patients with previously treated advanced PDAC. EXPERIMENTAL DESIGN: I...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Main Authors: Ko, Andrew H., Bekaii-Saab, Tanios, Van Ziffle, Jessica, Mirzoeva, Olga M., Joseph, Nancy, Talasaz, AmirAli, Kuhn, Peter, Tempero, Margaret A., Collisson, Eric A., Kelley, R. Kate, Venook, Alan P., Dito, Elizabeth, Ong, Anna, Ziyeh, Sharvina, Courtin, Ryan, Linetskaya, Regina, Tahiri, Sanaa, Korn, W. Michael
Formato: Artigo
Idioma:Inglês
Publicado: 2015
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4703532/
https://ncbi.nlm.nih.gov/pubmed/26251290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-0979
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares